Rahaman Jamal, Steiner Norma, Hayes Monica Prasad, Chuang Linus, Fishman David, Gretz Iii Herbert
Mount Sinai School of Medicine, New York, NY, USA.
Mt Sinai J Med. 2009 Dec;76(6):577-88. doi: 10.1002/msj.20143.
This review highlights significant recent developments and trends in chemotherapy for major gynecologic malignancies, i.e., ovarian cancer, endometrial cancer, uterine sarcomas, gestational trophoblastic neoplasia, and cervical cancer. In ovarian cancer, chemotherapeutic options for early, advanced and recurrent disease are in the adjuvant setting as well as in the neoadjuvant setting are explored. For uterine cancer, adjuvant chemotherapy is employed for high risk epithelial subtypes with early disease, such as uterine papillary serous carcinomas, uterine carcinosarcomas and leiomyosarcomas, advanced stage cases, as well as recurrent disease. The review then proceeds to further discuss the appropriate treatment based on the International Federation of Gynecology and Obstetrics prognostic scoring system for gestational trophoblastic neoplasia. Finally, chemotherapy is utilized in cervical cancer as neo-adjuvant therapy prior to surgery or radiation, as a sensitizer concomitantly with radiation therapy or for the treatment of advanced and recurrent disease.
本综述重点介绍了主要妇科恶性肿瘤(即卵巢癌、子宫内膜癌、子宫肉瘤、妊娠滋养细胞肿瘤和宫颈癌)化疗方面近期的重大进展和趋势。在卵巢癌中,探讨了早期、晚期和复发性疾病在辅助治疗以及新辅助治疗中的化疗选择。对于子宫癌,辅助化疗用于早期疾病的高危上皮亚型,如子宫乳头状浆液性癌、子宫癌肉瘤和平滑肌肉瘤,晚期病例以及复发性疾病。然后,该综述继续根据国际妇产科联合会妊娠滋养细胞肿瘤预后评分系统进一步讨论适当的治疗方法。最后,化疗在宫颈癌中用作手术或放疗前的新辅助治疗,作为放疗的增敏剂或用于治疗晚期和复发性疾病。